Listener Q&A: Drug Price Controls, EU Tariffs, and the August Recess

https://is1-ssl.mzstatic.com/image/thumb/Podcasts211/v4/c5/b1/39/c5b139ed-cd53-57d0-fed7-9d9eccd39600/mza_4610784360549851808.jpg/600x600bb.jpg

Making Medicine

Incubate Coalition

50 episodes

4 days ago

There's a scientific breakthrough in your medicine cabinet. But how did it get there?

At a time when medicines are helping us all live longer and healthier lives, this podcast will explore where these taken-for-granted miracles come from, how many of them almost never happened, where the life science ecosystem is taking us next, and most importantly, what it means for patients.

From chance meetings that led to new ideas, to risky investments that never pay off, hear from the people behind today's and tomorrow's treatments, vaccines, technologies, devices, and yes, cures.

In this golden age of health discovery and innovation fueled by record breaking investment in the life sciences, we'll bring guests who really understand what it means to be Making Medicine.

Health & Fitness

RSS

All content for Making Medicine is the property of Incubate Coalition and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.

Health & Fitness

https://d3wo5wojvuv7l.cloudfront.net/t_rss_itunes_square_1400/images.spreaker.com/original/63e60dcfcb6a53b07f7b9849742d611e.jpg

Listener Q&A: Drug Price Controls, EU Tariffs, and the August Recess | Making Medicine Podcast

Making Medicine

10 minutes

3 months ago

Listener Q&A: Drug Price Controls, EU Tariffs, and the August Recess | Making Medicine Podcast

In this week’s special Q&A episode, John Stanford tackles your biggest questions from around the biotech and policy world. From the growing list of drug price controls under the IRA to the newly announced 15% EU tariffs on medicines, there's a lot at stake for patients, companies, and innovation. John also breaks down the temporary NIH funding freeze, what it means for research, and why August recess matters more than you think.

What impact do you think drug price controls will have on innovation?
Should medicines be included in international tariff negotiations?
What policies should Congress prioritize this fall?

📱If you're new to the Making Medicine Podcast, we're happy you're here! Follow us for more:
https://x.com/MakingMedPod
https://www.instagram.com/makingmedicinepod/
https://www.linkedin.com/showcase/making-medicine-podcast/about/?viewAsMember=true

Timestamps:
0:00 Tech setup and behind-the-scenes
3:37 Welcome to the Making Medicine Podcast
4:16 Breaking news: FDA's SBER director steps down
4:58 Are we moving toward more price controls on drugs?
7:47 New EU trade deal and tariffs on pharmaceuticals
10:08 How the IRA continues to impact the investment environment
12:31 Did the White House freeze NIH funding?
15:10 What is August recess and why it matters
16:53 Final thoughts and call for listener questions